Your browser is no longer supported. Please, upgrade your browser.
JNJ Johnson & Johnson daily Stock Chart
Johnson & Johnson
IndexDJIA S&P500 P/E23.24 EPS (ttm)5.37 Insider Own0.02% Shs Outstand2.75B Perf Week-0.30%
Market Cap343.53B Forward P/E17.58 EPS next Y7.10 Insider Trans-25.65% Shs Float2.75B Perf Month7.05%
Income15.03B PEG3.63 EPS next Q1.66 Inst Own66.90% Short Float0.88% Perf Quarter11.43%
Sales70.88B P/S4.85 EPS this Y-3.90% Inst Trans-0.16% Short Ratio3.43 Perf Half Y23.90%
Book/sh26.40 P/B4.73 EPS next Y6.15% ROA- Target Price125.53 Perf Year29.75%
Cash/sh- P/C- EPS next 5Y6.41% ROE- 52W Range80.04 - 126.07 Perf YTD23.22%
Dividend3.20 P/FCF- EPS past 5Y2.80% ROI16.90% 52W High-1.09% Beta0.57
Dividend %2.56% Quick Ratio- Sales past 5Y2.60% Gross Margin69.60% 52W Low55.79% ATR1.19
Employees127100 Current Ratio- Sales Q/Q3.90% Oper. Margin25.50% RSI (14)74.94 Volatility0.68% 0.96%
OptionableYes Debt/Eq- EPS Q/Q-10.90% Profit Margin21.20% Rel Volume0.46 Prev Close124.77
ShortableYes LT Debt/Eq- EarningsJul 19 BMO Payout41.70% Avg Volume7.04M Price124.69
Recom2.40 SMA201.14% SMA505.39% SMA20016.59% Volume2,254,851 Change-0.06%
Jul-21-16Reiterated Deutsche Bank Hold $125 → $142
Jul-20-16Reiterated UBS Buy $126 → $137
Jul-20-16Reiterated RBC Capital Mkts Outperform $125 → $133
May-20-16Initiated Standpoint Research Sell $94
Apr-20-16Reiterated RBC Capital Mkts Outperform $122 → $125
Apr-20-16Reiterated Piper Jaffray Neutral $105 → $106
Apr-15-16Reiterated RBC Capital Mkts Outperform $114 → $122
Mar-14-16Upgrade Goldman Sell → Neutral
Dec-01-15Upgrade Barclays Equal Weight → Overweight $101 → $115
Oct-05-15Resumed Piper Jaffray Neutral $105
May-21-15Reiterated Deutsche Bank Hold $106 → $110
Dec-08-14Reiterated RBC Capital Mkts Outperform $110 → $114
Jul-16-14Reiterated Deutsche Bank Hold $102 → $107
Apr-17-14Reiterated Argus Buy $104 → $116
Apr-16-14Reiterated RBC Capital Mkts Outperform $104 → $106
Jan-10-14Downgrade Barclays Overweight → Equal Weight $99
Jan-07-14Upgrade RBC Capital Mkts Sector Perform → Outperform $88 → $104
Dec-16-13Reiterated Deutsche Bank Hold $93 → $95
Jul-18-13Reiterated Argus Buy $96 → $104
Jul-17-13Reiterated Barclays Overweight $95 → $99
Jul-28-16 10:34AM  Better Buy: Johnson & Johnson vs. Pfizer at Motley Fool
09:07AM  What Drove Edwards Lifesciences THVT Revenues in 2Q16?
01:00AM  New crop of robots to vie for space in the operating room
Jul-27-16 02:46PM  The 411 On Intel And Johnson & Johnson at Forbes
11:04AM  What Is Johnson & Johnsons Valuation?
10:26AM  Top 10 Dividend Aristocrats to Buy at a Discount Now
10:21AM  The Drug-Price War Just Took a Big New Twist at Motley Fool
10:00AM  Johnson & Johnson Is Getting Rather Expensive
09:20AM  5 Best Stocks to Buy for the Next 50 Years
09:08AM  Will Bristol-Myers Squibb See Higher Sales for Eliquis in 2Q16?
09:04AM  What Do Analysts Estimate for Johnson & Johnson?
08:16AM  Key Takeaways From Johnson & Johnson's Q2 Earnings Report at Motley Fool
08:00AM  Experimental Tau Protein Drug Tangled Up in Late-Stage Alzheimer's Study Failure
07:00AM  GSK chases next biotech asthma drug with $230 mln J&J deal
Jul-26-16 02:39PM  Will MNKs Segmental Growth Result in a 3Q16 Earnings Surprise?
02:20PM  3 Things to Watch as Celgene Corporation Reports Earnings at Motley Fool
02:09PM  FDA enhances warnings on group of strong antibiotics Reuters
11:56AM  Companies Hit 52-Week Highs
11:35AM  Tokai's shares tumble as it halts prostate-cancer drug trial at
11:18AM  What to Expect from Zimmer Biomet Holdings 2Q16 Earnings
11:04AM  Whats Johnson & Johnsons Guidance for 2016?
09:40AM  5 Best Stocks to Buy for the Next 50 Years at Kiplinger
09:07AM  One Biotech Plays Red Light, Green Light With the FDA at Motley Fool
09:04AM  What Key Developments Did JNJ Announce in 2Q16?
Jul-25-16 04:05PM  The Death Of Brand Loyalty: Cultural Shifts Mean It's Gone Forever at Forbes
02:24PM  Bristol-Myers Squibbs 2Q16 Estimates: Expect Growth!
12:50PM  Is Johnson & Johnson ready for pullback?
11:04AM  How Did JNJs Medical Devices Segment Perform in 2Q16?
11:04AM  Analysts Recommendations for JNJ after 2Q16 Earnings
09:30AM  The Zacks Analyst Blog Highlights: Bank of America, Chevron, Exxon Mobil, Johnson & Johnson and McDonald
09:05AM  How Did Johnson & Johnsons Consumer Segment Perform in 2Q16?
09:05AM  How Did JNJs Medical Devices Business Fare in 2Q16?
Jul-24-16 11:40AM  3 Important Takeaways From Johnson & Johnson's Second-Quarter Earnings at Motley Fool
01:51AM  UnitedHealth Reports 28% Sales Growth in 2nd Quarter
Jul-23-16 12:04PM  3 Healthcare Stocks to Hold Forever at Motley Fool
Jul-22-16 07:03PM  2 Cheap High-Yield Dividend Stocks for Your Retirement Portfolio at Motley Fool
06:04PM  Pharma Industry Outlook: Fundamentals Remain Strong
05:22PM  Johnson & Johnson Reports 4% Sales Growth for the Second Quarter
04:39PM  [$$] Johnson & Johnson's Acclarent Unit in $18 Million U.S. Settlement at The Wall Street Journal
03:42PM  Better Buy: Intuitive Surgical, Inc. vs. Johnson & Johnson at Motley Fool
01:28PM  How St. Jude Medical Beat 2Q16 Wall Street Estimates
01:14PM  How Did JNJs Pharmaceutical Segment Fare in 2Q16?
01:14PM  How Did Johnson & Johnsons Segments Perform in 2Q16?
01:14PM  Why Johnson & Johnsons 2Q16 Profits Fell by 11.5%
11:05AM  J&J unit Acclarent to pay $18 mln to settle false claims case Reuters
10:21AM  Animal Spirits Have Returned
09:00AM  Don't Disrespect This Bull Market
06:21AM  11 Big Brands Stats That Will Blow You Away at Motley Fool
Jul-21-16 06:50PM  Intuitive Surgicals Stock Rises amid Higher-than-Expected 2Q16 Earnings
05:50PM  Is the Earnings Picture Improving?
05:25PM  What Will Happen to the Stock Market When Interest Rates Rise? Part 1
04:52PM  Two Former Johnson & Johnson Execs Just Got Convicted for Improper Marketing at Fortune
03:50PM  Johnson & Johnson (JNJ) Gets Price Target Hike at Deutsche Bank
02:01PM  Research Reports on Facebook (FB), Tesla (TSLA) & Others
02:00PM  3 Healthcare ETFs to Buy as JNJ Beats Q2 Earnings
01:49PM  Inside the Foreign Exchange Impact on Novartiss Growth in 2Q16
01:26PM  The Best Long-Term Stocks to Buy at Motley Fool
12:08PM  Sell In May And Rotate at Forbes
11:28AM  How Were Johnson & Johnsons 2Q16 Earnings Trending?
11:27AM  How Did Johnson & Johnson Fare in 2Q16?
11:22AM  Johnson & Johnson :JNJ-US: Earnings Analysis: Q2, 2016 By the Numbers : July 21, 2016
10:12AM  Johnson & Johnsons Stock Surges after 2Q16 Earnings
09:03AM  These 5 Healthcare Stocks Have Huge Dividend Yields -- Are Any Worth Buying? at Motley Fool
08:40AM  Opioid Addiction: What To Do When A Loved One Is Hooked, According To Science
Jul-20-16 05:36PM  [$$] Jury Acquits Former Johnson & Johnson Unit Execs of Felony Fraud at The Wall Street Journal
05:11PM  J&J unit's former execs convicted of unapproved marketing Reuters
01:24PM  10 Best Dividend Stocks to Own Now for a Safe Retirement
10:22AM  Valeant Pharmaceuticals: Two for Two at
10:12AM  Why Richard Bernstein Thinks Investors Are Being Short-Sighted
10:03AM  3 Compelling Reasons to Buy Johnson & Johnson Following Earnings
09:30AM  Zacks Market Edge Highlights: Lockheed Martin, Johnson & Johnson, IBM, AMN Healthcare Services and Ambarella
08:55AM  Top Analyst Upgrades and Downgrades: Johnson & Johnson, Lockheed Martin, MGIC Investment, TransCanada, Verizon and More at 24/7 Wall St.
08:30AM  Global stocks resilient amid solid corporate earnings
07:00AM  Terrific Companies at Terrible Prices at Morningstar
06:49AM  Can Johnson & Johnson Keep Soaring Higher?
06:00AM  'Mad Money' Lightning Round: Take Bristol-Myers Over Juno
12:17AM  [$$] Currency Pain Relief for Johnson & Johnson at The Wall Street Journal
12:16AM  [$$] Johnson & Johnson Raises Guidance, Buoyed by Pharma Growth at The Wall Street Journal
Jul-19-16 08:20PM  Jim Cramer's 'Mad Money' Recap: Why Some Stocks Pass Earnings Test and Others Fail
07:13PM  Microsoft in Focus as Stock Valuation Gains Ease Slightly
07:01PM  Cramer: In Earnings Tests, JNJ Gets an A While Netflix Flunks
05:50PM  Netflix and Philip Morris stumble; VMware and Lockheed climb
05:42PM  Should You Buy Stocks at the All Time Highs?
05:22PM  Johnson & Johnson Boosts Dow, Netflix Pressures the S&P 500
04:27PM  Closing Bell: S&P Cuts Outlook on Deutsche; Dow Seals New Record at TheStreet
04:21PM  Intuitive Surgical Posts Q2 EPS, Sales Beat As Da Vinci Sales Rise
04:11PM  Markets Right Now: US end mostly lower
04:01PM  McDonalds, J&J Buoy DJIA on Tuesday at 24/7 Wall St.
03:56PM  Pisani: What to expect from Microsoft and United
03:25PM  Stocks Mixed; McDonald's, J&J Buoy Dow; Facebook Vies For Breakout
02:52PM  Johnson & Johnson's Unstylish Sprawl Looks Good at Bloomberg
02:44PM  Johnson & Johnson Hits Record High Despite Declines in Baby Care
01:48PM  Johnson & Johnson tops 2Q forecasts despite profit drop
01:33PM  Johnson & Johnson (JNJ) Stock Rises, CFO Talks M&A
01:29PM  US STOCKS-Wall St moves lower on mixed earnings reports
12:58PM  Top trades for the 2nd half: Johnson & Johnson, United Co...
12:52PM  Johnson & Johnson raises 2016 forecast, shares touch record high
12:51PM  [$$] Currency Pain Relief for Johnson & Johnson at The Wall Street Journal
12:38PM  ETFs with exposure to Johnson & Johnson : July 19, 2016
12:25PM  Stocks Modestly Lower After Tech Earnings
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates through three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand name; oral care products under the LISTERINE brand name; skin care products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, LUBRIDERM, NEUTROGENA, and RoC brand names; women's health products, such as sanitary pads under the STAYFREE and CAREFREE, and o.b. tampon brand names; wound care products, including adhesive bandages under the BAND-AID brand name and first aid products under the NEOSPORIN brand name. This segment also provides over-the-counter medicines, including acetaminophen products under the TYLENOL brand name; cold, flu, and allergy products under the SUDAFED brand name; allergy products under the BENADRYL and ZYRTEC brand names; ibuprofen products under the MOTRIN IB brand name; and heartburn products under the PEPCID brand name. The Pharmaceutical segment provides various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment offers orthopaedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; blood glucose monitoring and insulin delivery products; and disposable contact lenses. The company offers its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kapusta Ronald AController, CAOJul 22Sale125.012,935366,89625,725Jul 25 03:18 PM
Kapusta Ronald AController, CAOJul 21Option Exercise58.332,935171,19928,660Jul 25 03:18 PM
Kapusta Ronald AController, CAOJun 07Option Exercise58.333,000174,99028,725Jun 09 04:11 PM
Pruden Gary JExec VP, WW Chair, Med DevicesJun 07Sale116.039,7351,129,55243,630Jun 09 04:12 PM
Kapusta Ronald AController, CAOJun 07Sale115.793,000347,38125,725Jun 09 04:11 PM
Kapusta Ronald AController, CAOMay 10Option Exercise58.333,957230,81229,682May 12 05:09 PM
Kapusta Ronald AController, CAOMay 10Sale114.773,957454,15725,725May 12 05:09 PM
Caruso Dominic JVP, Finance; CFOFeb 08Option Exercise0.0029,0050125,466Feb 10 06:02 PM
Gorsky AlexChairman, CEOFeb 08Option Exercise0.0067,9330197,441Feb 10 06:02 PM
PETERSON SANDRA EGroup Worldwide ChairmanFeb 08Option Exercise0.007,633037,943Feb 10 06:03 PM
Fasolo PeterVP, Global Human ResourcesFeb 08Option Exercise0.0018,777056,512Feb 10 06:03 PM
Ullmann Michael HVP, General CounselFeb 08Option Exercise0.0016,697098,071Feb 10 06:03 PM
Stoffels PaulusChief Scientific OfficerFeb 08Option Exercise0.0028,2420131,104Feb 10 06:03 PM
Kapusta Ronald AController, CAOFeb 08Option Exercise0.002,598026,023Feb 10 06:03 PM
Fasolo PeterVP, Global Human ResourcesFeb 03Option Exercise72.54144,56810,486,963182,303Feb 04 06:04 PM
Fasolo PeterVP, Global Human ResourcesFeb 03Sale104.12144,56815,052,42037,735Feb 04 06:04 PM
Fasolo PeterVP, Global Human ResourcesFeb 02Option Exercise72.546,817494,50544,552Feb 04 06:04 PM
Fasolo PeterVP, Global Human ResourcesFeb 02Sale104.096,817709,58837,735Feb 04 06:04 PM
Caruso Dominic JVP, Finance; CFOJan 15Option Exercise0.0011,6020100,336Jan 20 07:25 PM
Fasolo PeterVP, Global Human ResourcesJan 15Option Exercise0.007,511040,578Jan 20 07:25 PM
Gorsky AlexChairman, CEOJan 15Option Exercise0.0027,1730140,534Jan 20 07:25 PM
PETERSON SANDRA EGroup Worldwide ChairmanJan 15Option Exercise0.003,053031,616Jan 20 07:25 PM
Ullmann Michael HVP, General CounselJan 15Option Exercise0.006,679083,907Jan 20 07:25 PM
Kapusta Ronald AController, CAOJan 15Option Exercise0.003,896024,699Jan 20 07:25 PM
Stoffels PaulusChief Scientific OfficerJan 15Option Exercise0.0011,2970106,585Jan 20 07:25 PM
PETERSON SANDRA EGroup Worldwide ChairmanDec 17Option Exercise0.0021,688040,730Dec 21 05:09 PM
Ullmann Michael HVP, General CounselNov 20Option Exercise58.3422,6261,320,00194,878Nov 24 01:00 PM
Ullmann Michael HVP, General CounselNov 20Sale102.4717,6501,808,54377,228Nov 24 01:00 PM
Caruso Dominic JVP, Finance; CFONov 02Option Exercise58.3420,5691,199,995109,303Nov 04 05:05 PM
Caruso Dominic JVP, Finance; CFONov 02Sale102.2120,5692,102,42388,734Nov 04 05:05 PM
Kapusta Ronald AController, CAOOct 23Option Exercise58.346,239363,98327,042Oct 27 03:38 PM
Kapusta Ronald AController, CAOOct 23Sale99.686,239621,90420,803Oct 27 03:38 PM
PRINCE CHARLESDirectorAug 06Buy99.252,500248,13225,645Aug 10 12:49 PM